← Trials/Trial dossier/NCT03883412

ZQL007

UnknownPhase 4

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

60

estimated

Study population

Type 2 diabetes

Key I/E criterion

HbA1c ≤8.5%

Primary endpoint

Microvascular Blood Volume - change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03883412
Org study ID20320

Timeline

Milestones

Study start2019-02-28actual
Study first posted2019-03-20actual
Last update posted2023-12-20actual
Primary completion2025-06estimated (month precision)
Study completion2025-12estimated (month precision)

Assets

Investigational agents

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age21 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

Age 21-60
A1C ≤ 8.5%
Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
On stable dose of oral hypoglycemic agents >4 months
On stable dose of other medications for >4 months

Exclusion criteria

Taking Insulin
Smoking presently or in the past 6 months
BP >160/90
BMI >35
Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
Pregnant or breastfeeding.
Known hypersensitivity to perflutren (contained in Definity)

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Other (unclassified)
2
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Insulin Sensitivity-Change from baseline

Time frame:16 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Augmentation Index - change from baseline

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint

Flow Mediated Dilation - change from baseline

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint

Pulse Wave Velocity - change from baseline

Time frame:16 weeks

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Microvascular Blood Volume - change from baseline

Time frame:16 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Post Ischemic Flow Velocity-Change from baseline

Time frame:16 weeks

change from baseline, descriptive

Publications (44)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.